Santhera Pharmaceuticals Holding AG (SWX:SANN)
10.22
-0.30 (-2.85%)
Oct 21, 2025, 5:31 PM CET
SWX:SANN Revenue
Santhera Pharmaceuticals Holding AG had revenue of 24.01M CHF in the half year ending June 30, 2025, with 509.62% growth. This brings the company's revenue in the last twelve months to 49.02M, down -56.85% year-over-year. In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M, down -62.17%.
Revenue (ttm)
49.02M
Revenue Growth
-56.85%
P/S Ratio
2.79
Revenue / Employee
620.46K
Employees
79
Market Cap
136.62M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
Dec 31, 2022 | 7.47M | 9.07M | -568.53% |
Dec 31, 2021 | -1.60M | -16.60M | -110.63% |
Dec 31, 2020 | 15.01M | -60.37M | -80.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Sandoz Group AG | 8.42B |
Alcon | 7.97B |
Lonza Group AG | 7.09B |
Galenica AG | 4.03B |
Sonova Holding AG | 3.87B |
Galderma Group AG | 3.73B |
Santhera Pharmaceuticals Holding AG News
- 13 days ago - Santhera Partners With Biomedica To Distribute Agamree In Russia - Nasdaq
- 19 days ago - Health Canada Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy - Nasdaq
- 22 days ago - Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Santhera Pharmaceuticals Holding AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Santhera Pharma Stock Down On Wider H1 Loss; Is AGAMREE On Track? - Nasdaq
- 7 weeks ago - Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India - GlobeNewsWire
- 2 months ago - Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries - GlobeNewsWire
- 6 months ago - Santhera Pharmaceuticals reports FY results - Seeking Alpha